Hamamoto, S.; Tasaki, Y.; Morikawa, T.; Naiki, T.; Etani, T.; Taguchi, K.; Iwatsuki, S.; Unno, R.; Takeda, T.; Nagai, T.;
et al. Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma. J. Clin. Med. 2024, 13, 3365.
https://doi.org/10.3390/jcm13123365
AMA Style
Hamamoto S, Tasaki Y, Morikawa T, Naiki T, Etani T, Taguchi K, Iwatsuki S, Unno R, Takeda T, Nagai T,
et al. Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma. Journal of Clinical Medicine. 2024; 13(12):3365.
https://doi.org/10.3390/jcm13123365
Chicago/Turabian Style
Hamamoto, Shuzo, Yoshihiko Tasaki, Toshiharu Morikawa, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Shoichiro Iwatsuki, Rei Unno, Tomoki Takeda, Takashi Nagai,
and et al. 2024. "Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma" Journal of Clinical Medicine 13, no. 12: 3365.
https://doi.org/10.3390/jcm13123365
APA Style
Hamamoto, S., Tasaki, Y., Morikawa, T., Naiki, T., Etani, T., Taguchi, K., Iwatsuki, S., Unno, R., Takeda, T., Nagai, T., Kawase, K., Mimura, Y., Sugiyama, Y., Okada, A., Furukawa-Hibi, Y., & Yasui, T.
(2024). Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma. Journal of Clinical Medicine, 13(12), 3365.
https://doi.org/10.3390/jcm13123365
